hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-15. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Here, when a = b, Poiseuille flow for circular pipe is recovered and when a → ∞, plane Poiseuille flow is recovered. More explicit solutions with cross-sections such as snail-shaped sections, sections having the shape of a notch circle following a semicircle, annular sections between homofocal ellipses, annular sections between non-concentric circles are also available, as reviewed by Ratip Berker.
=== Breeding === Black neon tetras can be spawned rather easily if the water quality is right. Before attempting to breed the black neon tetra, breeders condition the prospective parents with live food. Fish around one year old can be suitable for breeding. The sex of the fish is determined by its body shape, the female being much rounder and more plump than the males. Although the black neon tetra can be kept in water harder and more alkaline than its natural habitat, for breeding it is necessary to be closer to what it would feel like in the Amazon. Breeding the Black neon tetra requires acidic water with no more than four degrees of hardness. The black neon tetra is an egg scatterer, laying adhesive (sticky) eggs over plants. One female can produce several hundred eggs. The parents eat their own eggs, so the parents are normally removed after spawning. As with many fish, the black neon tetra often spawns in the early morning. Raising the fry can be more difficult because of their small size. The first food will normally be protozoa (infusoria), then Daphnia.
The reaction of Androstenedione [63-05-8] (1) with triethyl orthoformate convers the enone into the corresponding enol ether, 3-Ethoxyandrosta-3,5-dien-17-one [972-46-3] (2). Grignard addition of methyl magnesium halide gives (3). Catalytic hydrogenation reduces the C5=C6 olefin giving (4). Hydrolysis of the product in aqueous acid completed the synthesis of mestanolone (5).
Rosemary Pauline West (née Letts; born 29 November 1953) is an English serial killer, serial rapist and child molester who collaborated with her husband, Fred West, in the torture and murder of at least ten young women between 1973 and 1987; she also murdered Fred's eight-year-old stepdaughter, Charmaine, in 1971. The majority of these murders took place at the West residence at 25 Cromwell Street in Gloucester. Rose West is currently an inmate at New Hall Prison in Flockton, West Yorkshire, after being convicted in 1995 and sentenced to ten life terms with a whole life order. Fred West died by suicide in prison that same year while awaiting trial, following the couple's arrest in 1994.
Sources: en.wikipedia.org
An ongoing conflict between the Lebanese militant group Hezbollah and Israel began on 8 October 2023, when Hezbollah launched rockets and artillery at Israeli positions following Hamas's October 7 attacks on Israel. The conflict escalated into a prolonged exchange of bombardments, leading to extensive displacement in Israel and Lebanon. The conflict is part of the broader Middle Eastern crisis that began with Hamas's attack, with the short Israeli invasion of Lebanon in 2024 marking the largest escalation of the Hezbollah–Israel conflict since the 2006 Lebanon War. In Arabic, the conflict (2023–2024) is referred to as the "Support War" or the "Gaza Support War." On 8 October 2023, Hezbollah started firing guided rockets and artillery shells at Israeli positions in the Shebaa Farms, which it said was in solidarity with Palestinians following the 7 October Hamas-led attack on Israel and beginning of Israeli bombing of the Gaza Strip. Israel retaliated by launching drone strikes and artillery shells at Hezbollah positions. Israel also carried out airstrikes throughout Lebanon and in Syria. In northern Israel, the ongoing conflict has forced approximately 96,000 individuals to leave their homes, while in Lebanon, over 1.4 million individuals had been displaced by late October. Hezbollah stated it would not stop attacks against Israel until it stops its military operations in Gaza; Israel said its attacks would continue until its citizens could return safely to the north.
The initial absence of U-233 and its daughter products in the MOX fuel results in a lower activity in region 3 of the figure at the bottom right, whereas for RGPu and WGPu the curve is maintained higher due to the presence of U-233 that has not fully decayed. Nuclear reprocessing can remove the actinides from the spent fuel so they can be used or destroyed (see Long-lived fission product § Actinides).
Glucagon is a hormone that generally opposes the action of insulin. It increases blood glucose by stimulating the production of glucose in the liver via glycogenolysis (breakdown of glycogen) and gluconeogenesis (production of glucose from non-carbohydrate sources). Glucagon also increases the breakdown of lipids and amino acids and the production of ketones. Unlike currently approved weight loss drugs, glucagon receptor agonists increase energy expenditure. Combination GLP-1/glucagon receptor agonists provide the thermogenic benefits of glucagon activation while almost eliminating hyperglycemia induced by glucagon receptor activation. Several such drugs have reached human trials for obesity, diabetes, and non-alcoholic fatty liver disease but adverse effects have hampered development. The most advanced of these drugs is mazdutide which is in a phase III trial as of 2023.
Henan Corps Hubei Corps Hunan Corps Inner Mongolia Corps Jiangsu Corps Jiangxi Corps Jilin Corps Liaoning Corps Ningxia Corps Qinghai Corps Two mobile detachments Shaanxi Corps Shanxi Corps Shandong Corps Shanghai Corps Two mobile detachments
A key challenge in cell transplantation therapies for Type 1 diabetes is hypoxia and low oxygen conditions in transplant environments that can impair the function and identity of stem cell-derived beta cells.
Sources: en.wikipedia.org
=== General === The croaking gourami is a fairly shy, peaceful fish that does well in most community aquaria, not causing problems with tankmates. Males can be fairly territorial and aggressive towards each other during breeding periods, but will not cause harm and can peacefully coexist given a large enough aquarium. This species requires a tank no smaller than 40 L (11 U.S. gal), preferably larger. The croaking gourami will prowl about all areas of the aquarium, preferring to lurk among reeds and under large leaves close to the water surface. At night, they might be found "sleeping" at the bottom, even resting on the substrate (which is not normally a cause for concern), or hovering motionless at the water surface. Like all members of the suborder Anabantoidei, if necessary, the croaking gourami can breathe atmospheric oxygen from above the water surface using a specialized labyrinth organ. It is important, therefore, that the surface of the water be exposed to fresh air, usually accomplished by keeping them in an open-top tank or using a hood that allows air ventilation. If the tank has good air pumps, this is not always needed, since the air pumps will refresh the air above the water. The aquarium should be heavily planted and have at least part of the surface shaded by broad leaves or floating plants, since the croaking gourami will become severely stressed in bare tanks without various hiding places. A darker substrate will make this fish feel comfortable and help show off its subtle colors.
English Defence League founder Tommy Robinson is charged by police with failing to comply with an order to stay away from the previous day's antisemitism march after attending the rally. 28 November An investigation by The Guardian finds that potentially toxic "forever chemicals" are present in the drinking water sources at 17 of the 18 water companies in England. Virgin Atlantic launches the world's first transatlantic flight by a large passenger plane using 100% sustainable aviation fuel. The passengerless journey is made by a Boeing 787 travelling from London Heathrow to New York. 29 November The coldest November night since 2010 is experienced by many parts of the UK, reaching as low as −8 °C (18 °F) in Aonach Mòr in the Scottish Highlands, with snow and ice warnings for various regions extending to Friday. Natural England announces that England will be getting a new National Park. The Chilterns, The Cotswolds and Dorset could become new National Parks. Nottingham City Council declares itself effectively bankrupt, with a £23m overspend forecast for the 2023–24 financial year. At Prime Minister's Questions, Sunak accuses the Greek prime minister of trying to "grandstand" over the Elgin Marbles when questioned about his decision to cancel a planned meeting with Mitsotakis. 30 November Matt Hancock, who served as health secretary from 2018 to 2021, appears at the latest stage of the COVID-19 inquiry. RMT members vote to accept a pay deal from 14 train companies, which ends a long-running series of strikes until at least spring 2024.
=== Gas chromatography === GC is a method involving the separation of different analytes within a sample of mixed gases. The separated gases can be detected multiple ways, but one of the most powerful detection methods for gas chromatography is mass spectrometry. After the gases separate, they enter the mass spectrometer and are analyzed. This combination not only separates the analytes, but gives structural information about each one. The GC sample must be volatile, or able to enter the gas phase, while also being thermally stable so that it does not break down as it is heated to enter the gas phase. Mass spectrometry ionization techniques requiring the sample to be in the gas phase have similar concerns. Electron ionization (EI) in mass spectrometry requires samples that are small molecules, volatile, and thermally stable, similar to that of gas chromatography. This ensures that as long as GC is performed on the sample before entering the mass spectrometer, the sample will be prepared for ionization by EI. Chemical ionization (CI) is another method that requires samples to be in the gas phase. This is so that the sample can react with a reagent gas to form an ion that can be analyzed by the mass spectrometer. CI has many of the same requirements in sample preparation as EI, such as volatility and thermal stability of the sample. GC is useful for sample preparation for this technique as well. One advantage of CI is that larger molecules separated by GC can be analyzed by this ionization method.
, that occupy zero volume, so that no part of the chain excludes another from any location. One can regard the segments of each such chain in an ensemble as performing a random walk (or "random flight") in three dimensions, limited only by the constraint that each segment must be joined to its neighbors. This is the ideal chain mathematical model. It is clear that the maximum, fully extended length L of the chain is
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.